Gracell Biotechnologies (Gracell Biotechnologies) Equity-to-Asset : 0.86 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Gracell Biotechnologies Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gracell Biotechnologies's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $222.13 Mil. Gracell Biotechnologies's Total Assets for the quarter that ended in Sep. 2023 was $258.97 Mil.

The historical rank and industry rank for Gracell Biotechnologies's Equity-to-Asset or its related term are showing as below:

GRCL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02 Med: 0.85 Max: 0.92
Current: 0.86

During the past 5 years, the highest Equity to Asset Ratio of Gracell Biotechnologies was 0.92. The lowest was 0.02. And the median was 0.85.

GRCL's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs GRCL: 0.86

Gracell Biotechnologies Equity-to-Asset Historical Data

The historical data trend for Gracell Biotechnologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gracell Biotechnologies Equity-to-Asset Chart

Gracell Biotechnologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

0.02

0.62

0.85

0.89

0.83

Gracell Biotechnologies Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Equity-to-Asset	Get a 7-Day Free Trial													0.83	0.83	0.82	0.83	0.86

Competitive Comparison of Gracell Biotechnologies's Equity-to-Asset

For the Biotechnology subindustry, Gracell Biotechnologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gracell Biotechnologies's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gracell Biotechnologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gracell Biotechnologies's Equity-to-Asset falls into.

Gracell Biotechnologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gracell Biotechnologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	197.336	/	237.571
	=

Gracell Biotechnologies's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	222.131	/	258.973
	=

Gracell Biotechnologies (NAS:GRCL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Gracell Biotechnologies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gracell Biotechnologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Gracell Biotechnologies (Gracell Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gracell Biotechnologies Inc (NAS:GRCL) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

218 Sangtian Street, Building 12, Block B, Phase II, Biobay Industrial Park, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.gracellbio.com

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.